Chemotherapy and EGFR inhibitor therapy
Two to four cycles of induction chemotherapy followed by concurrent
chemoradiotherapy were given to all patients. EGFR-positive patients
received Nimotuzumab, while EGFR-negative patients received Cetuximab
(Table 2). All patients received oral mucositis prophylaxis followed by
conventional mucositis treatment combined with quinolone antibiotics
[4].